Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc.SNOA · Entity 8177 | Chief Financial Officer | April 23, 2020 | April 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sonoma Pharmaceuticals, Inc.
Report date April 23, 2020 · Filed April 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 2,609 |
Reported balance
After 2020-04-23 transaction · row 1
1 source rowRow 1 · 2020-04-23 · Grant · Acquired 2,609 · Balance 2,609 F1: The award will vest in three years, with the first third vesting on April 14, 2021, second third will vest on April 14, 2022 and remaining third will vest on April 14, 2023. If the Issuer terminates Mr. Edwards prior to April 14, 2021, all stock will vest immediately on the termination date. If the Issuer terminates Mr. Edwards on or after April 14, 2021, including by not renewing this agreement, all unvested stock will be forfeited. If Mr. Edwards terminates, all unvested stock will be forfeited. |
Filing footnotes · ownership attribution and instrument terms
F1: The award will vest in three years, with the first third vesting on April 14, 2021, second third will vest on April 14, 2022 and remaining third will vest on April 14, 2023. If the Issuer terminates Mr. Edwards prior to April 14, 2021, all stock will vest immediately on the termination date. If the Issuer terminates Mr. Edwards on or after April 14, 2021, including by not renewing this agreement, all unvested stock will be forfeited. If Mr. Edwards terminates, all unvested stock will be forfeited.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2020 Filed Apr 24, 2020 16:17 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantCommon Stock, $0.0001 par value | 2,609 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-20-001273 · ownership.xml · nonDerivative · entry 1 Edwards Robert Grant · CIK 0001810327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,609 F1 · price: The award will vest in three years, with the first third vesting on April 14, 2021, second third will vest on April 14, 2022 and remaining third will vest on April 14, 2023. If the Issuer terminates Mr. Edwards prior to April 14, 2021, all stock will vest immediately on the termination date. If the Issuer terminates Mr. Edwards on or after April 14, 2021, including by not renewing this agreement, all unvested stock will be forfeited. If Mr. Edwards terminates, all unvested stock will be forfeited. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.